Bicycle Therapeutics(BCYC) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results Multiple abstracts accepted for presentation at 2025 ASCO and AACR annual meetings underscore breadth of Bicycle technology and potential of oncology pipeline Phase 1/2 Duravelo-3 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer open and actively recruiting patients Bolstered business and clinical expertise with appointments to Board of Directors, Clinical Advisory Board and company ...